Registration
 
All news
Top Stories
Editors' Picks
Stocks
Crypto
Economics
Currencies
Commodities
Market Voices
Companies
Anastasiia Chabaniuk
Anastasiia Chabaniuk

Editas Medicine presents new preclinical data on EDIT-401 at EASCongress2026

Editas Medicine presents new preclinical data on EDIT-401 at EASCongress2026
Editas Medicine unveils EDIT-401 data

Editas Medicine presented new preclinical data this week at EASCongress2026, focusing on the progress of its lead in vivo development candidate, EDIT-401.

The company provided details supporting the continued advancement of this gene editing therapy for cardiovascular disease. The developments, shared via an official press release, underscore Editas Medicine's ongoing work in gene editing research as it seeks to address unmet medical needs.

Editas Medicine previously announced first quarter 2026 results and business updates, offering details on its gene editing programs. Earlier this year, the company also presented preclinical data on cardiovascular disease at the ASGCT and TIDES USA annual meetings. The latest preclinical findings extend Editas Medicine’s recent pipeline activity.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Editor's Picks for You

Bitcoin price prediction based on MVRV: Indicator points to BTC undervaluation
  • By Mikhail Vnuchkov
  • 4 hours ago
Bitcoin price prediction based on MVRV: Indicator points to BTC undervaluation
Editors' Picks
Amazon flooded with AI books: Crisis of trust in literature market
  • By Eugene Komchuk
  • Yesterday
Amazon flooded with AI books: Crisis of trust in literature market
Editors' Picks
From stablecoins to the metaverse: Meta's biggest bets that failed
  • By Pavlo Kot
  • 27.06.2026
From stablecoins to the metaverse: Meta's biggest bets that failed
Editors' Picks
All Editors' Top Picks

Latest Editas Medicine News

Editas Medicine team joins J.P. Morgan Corporate Challenge to boost workplace collaboration
  • By Oleg Tkachenko
  • 16 hours ago
Editas Medicine team joins J.P. Morgan Corporate Challenge to boost workplace collaboration
Companies
#Editas Medicine
Editas Medicine to present future-shaping innovations in genetic medicine at ECB2026
  • By Artem Shendetskii
  • 24.06.2026
Editas Medicine to present future-shaping innovations in genetic medicine at ECB2026
Companies
#Editas Medicine
Editas Medicine CEO to join MIT panel on pipeline prioritization at Longwood Healthcare Leaders event
  • By Anastasiia Chabaniuk
  • 12.06.2026
Editas Medicine CEO to join MIT panel on pipeline prioritization at Longwood Healthcare Leaders event
Companies
#Editas Medicine
All Editas Medicine News
  • Mikhail Vnuchkov
  • 4 hours ago
Bitcoin price prediction based on MVRV: Indicator points to BTC undervaluation
  • Eugene Komchuk
  • Yesterday
Amazon flooded with AI books: Crisis of trust in literature market
  • Pavlo Kot
  • 27.06.2026
From stablecoins to the metaverse: Meta's biggest bets that failed
  • Johnathan Maverick
  • 26.06.2026
Gold and silver: Why to buy in July
  • Anastasiia Chabaniuk
  • 26.06.2026
AI push hits Apple: MacBook and iPad prices rise as shares fall
  • Yaroslav Dmytrenko
  • 9 min ago
Joe Nakamoto: German government sold 50,000 BTC nearly two years ago
  • Artem Shendetskii
  • 10 min ago
Companies investing heavily in AI report 10 percent employment growth, David Sacks notes
  • Hanna Syniavska
  • 10 min ago
Andre Cronje: ftUSD yield holding steady at 13% on USDC and USDT
  • Elena Nikulina
  • 14 min ago
Steve Hou: U.S. AI capex spending far exceeds China
  • Jose Antonio Gastelum
  • 20 min ago
Alex Thorn: Casascius coin dashboard by w_s_bitcoin highlighted for crypto enthusiasts
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.
Top News
  • Olga Shendetskaya
  • 2 hours ago
ECB rate path remains uncertain despite U.S.-Iran ceasefire
ECB rate path remains uncertain despite U.S.-Iran ceasefire
  • Andrey Mastykin
  • 4 hours ago
Brent and WTI decline as Gulf ceasefire hopes pressure crude
Brent and WTI decline as Gulf ceasefire hopes pressure crude
  • Igor Krasulya
  • 4 hours ago
Yen hits historic low as U.S. rate gap keeps pressure on Japan
Yen hits historic low as U.S. rate gap keeps pressure on Japan
  • Eugene Komchuk
  • 5 hours ago
Securitize to list on NYSE after merger with Cantor Equity Partners II
Securitize to list on NYSE after merger with Cantor Equity Partners II
  • Eugene Komchuk
  • 22 hours ago
Germany leads EU in MiCA crypto licenses
Germany leads EU in MiCA crypto licenses
Live News
  • Mykhailo Ihnatenko
  • Now
Intel nears ATH despite sector-wide profit-taking
  • Mykhailo Ihnatenko
  • Now
Silver heads for its worst month since 2011
  • Anton Kharitonov
  • Now
Bitcoin stays below $60,000 under ETF pressure
  • Anton Kharitonov
  • Now
WTI holds support after decline
  • Anton Kharitonov
  • Now
Natural gas under pressure from U.S. inventories
Who We Are
Business Solutions
For Users
TU News
Popular Sections
Disclosures
CONTACT US
Legal
We are in Social Media
© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186
  • Risk disclosure:

    Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

    That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.

  • Disclaimer:

    Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

    Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.

  • Disclosure of advertisers and revenues:

    All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

    Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.

onepercentfortheplanet.org World Association of News Publishers https://gdpr.eu/ GDPR